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Abstract
Background: Patients were defined each successive month as either ‘chronic’ when more than 50% of the preceding 12 months
were PA culture positive, ‘intermittent’ when F50% of the preceding 12 months were PA culture positive, ‘free of PA’, with no
growth of PA for the previous 12 months, having previously been PA culture positive, or ‘never infected’, when PA had never
been cultured. Methods: Cross-sectional analysis of 146 children attending the Leeds Regional Cystic Fibrosis Centre was
performed to assess relationship between the new definition and clinical scores and investigations. The response variable was
regressed on age and sex and the residuals analysed using the Kruskal–Wallis test. Results: The ‘chronic’ group (18% of patients)
had significantly worse Shwachman–Kulczycki (SK) and Northern chest X-ray scores, and % predicted FEV values than the1
‘free’ (28%) or ‘never’ (20%) categories (P-0.004). The ‘intermittent’ group (34%) had a significantly higher SK score than
the ‘chronic’ group (P-0.0001), and a significantly lower % predicted FEV value than the ‘free’ or ‘never’ groups (P-0.0003).1
‘Chronic’ patients were significantly associated with a positive, and ‘never’ patients with a negative, PA antibody result (P-
0.001). Conclusions: The validity and importance of identifying these four subgroups is demonstrated. Previous definitions may
over-estimate the prevalence of chronic infection.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Pseudomonas aeruginosa is the most common path-
ogen causing chronic infection in people with cystic
fibrosis (CF) w1x. Chronic infection with this organism
has been shown to be associated with a lower FEV in1
childhood w2x, a faster decline in FEV despite optimal1
respiratory management w3,4x, a worse mortality rate
w5x, and shorter median survival w1x.
Currently there is no universally accepted definition
for chronic P. aeruginosa infection. In the UK the Cystic
Fibrosis Trust use the definition proposed by Brett et al.
in 1992 as ‘the regular culture of P. aeruginosa from
the sputum or respiratory secretions, on two or more
occasions, extending over 6 months or a shorter period
if accompanied by a sustained rise of anti-Pseudomonas
Abbreviations: PA: Pseudomonas aeruginosa; CF: Cystic fibrosis;
FEV1: Forced expiratory volume in one second; SK: Shwachman–
Kulczycki
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antibodies’ w6x. In Copenhagen chronic P. aeruginosa
infection is defined as ‘persistent presence of P. aeru-
ginosa for at least 6 consecutive months, or less when
combined with the presence of two or more P. aerugi-
nosa precipitins’, with intermittent P. aeruginosa colon-
isation defined as ‘culture of P. aeruginosa at least once
and the presence of normal levels of precipitating
antibodies against P. aeruginosa’ w7x. In Germany and
North America chronic P. aeruginosa colonisation is
defined as having more than 50% of cough swab or
sputum samples positive in a 12-month period w2,8x, or
by whether a patient’s last sputum sample of each year
grows P. aeruginosa w1x.
Modern CF care, particularly the success of P. aeru-
ginosa eradication policies w9x, has resulted in these
definitions becoming less appropriate for many patients
with CF. For example, a patient may grow P. aeruginosa
on two or more occasions and then, following eradica-
tion, not grow the organism again for many years.
A validated, universally accepted, and clinically use-
ful classification of patients infected with P. aeruginosa,
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particularly those chronically infected, would improve
patient care for the following reasons:
1. Treatment: Determining which patients require chron-
ic P. aeruginosa treatment protocols w10,11x.
2. Clinic Management: Enabling cohort isolation of
those patients that are at high risk of infecting other
CF patients with P. aeruginosa w12–14x.
3. Prognosis: Allowing better prognostic information for
patients and parents.
4. Audit: Enabling clinical effectiveness of anti-Pseudo-
monal strategies within the clinic to be assessed
quantitatively over time w7x.
5. Research: Facilitating the comparison of results from
different CF centres, and cumulative analyses such as
national CF databases.
As there is presently no established ‘gold-standard’
definition for P. aeruginosa infection it is not possible
to directly validate any new definition. However, it is
possible to assess face-validity by determining if a new
definition classifies patients appropriately in relation to
relevant clinical scores and investigations. Face validity
demonstrates that the measure reflects the content of the
concept in question w15x, and as the association of
chronic P. aeruginosa infection with clinical score w16x,
chest X-ray score w4x, percent predicted FEV w2,3x,1
height and weight w3x, and P. aeruginosa antibody level
w6x is already established, the validity of a new definition
can be best assessed in this way.
The accuracy of any definition will depend on the
frequency of sampling. The UK Cystic Fibrosis Trust
suggests sputum sampling at least every 2 months (six
times per year) in children and every 3 months (four
times per year) in adults w17x. If patients are sampled
less than this then any categorisation is likely to be
inaccurate. We would recommend that sampling should
be taken three monthly as a minimum as recommended
by the European Consensus on Antibiotic Therapy
against P. aeruginosa w10x.
The definition of chronic infection should be based
on microbiological results from cough swabs or sputum
samples as few centres have access to well-validated,
prompt P. aeruginosa antibody results. The monthly
categorisation should be independent of the multiplicity
of samples taken within any given month, to avoid bias
caused by patients having more frequent sampling dur-
ing exacerbations.
The aim of this study was to assess the validity of a
new definition for chronic P. aeruginosa infection that
meets these requirements.
2. Methods
2.1. Monthly culture status
Patients were defined each successive calendar month
as either:
1. Pseudomonas aeruginosa culture positive (one or
more P. aeruginosa positive cough swabs or sputum
cultures that month).
2. P. aeruginosa culture negative (all cough swab or
sputum cultures that month negative for P.
aeruginosa).
3. No cough swab or sputum culture performed that
month.
2.2. Infection status based on previous 12 months
Four distinct states of P. aeruginosa infection, impor-
tant in the management of individual patients and the
clinic, were defined by a local working party of clini-
cians, microbiologists and nursing staff. All the patients
in the clinic were categorised each month according to
their monthly P. aeruginosa status over the preceding
twelve calendar months on the following basis:
Chronic infection When more than 50% of months, when samples
had been taken, were P. aeruginosa culture
positive.
Intermittent When 50% or less of months, when samples
infection had been taken, were P. aeruginosa culture
positive.
Free of No growth of P. aeruginosa during the previous
infection twelve months, having previously been P. aeru-
ginosa culture positive.
Never P. aeruginosa never cultured from sputum or
cough swab.
2.3. Microbiological methods
Standard practice for patients receiving all of their
care at our Centre is to have a sputum or cough swab
sample taken at every clinic visit, with no more than
twelve weeks between visits.
Sputum samples were collected from all children who
could expectorate. Parents were encouraged to collect
sputum samples at home if their children expectorated
only rarely. When it was not possible to obtain sputum
samples and the child was well, cough swabs were
taken. If new infection was suspected clinically sputum
induction was attempted using hypertonic saline w18x.
P. aeruginosa was isolated from samples using stan-
dard microbiological methods. Briefly, sputum samples
were homogenised with an equal volume of Sputasol
(Oxoid Ltd, Basingstoke, UK) and incubated at 37 8C
for 30 min. 0.1 ml of homogenate was added to 5 ml
of peptone water, agitated, and 10 ml of this was used
to inoculate bactracin (10 mgyl)—chocolate agar.
Cough swabs were applied directly without dilution. All
plates were incubated at 37 8C in air for 48 h. Presump-
tive P. aeruginosa isolates were identified by colonial
morphology, gram stain, positive cytochrome oxidase
test, and biochemical profiling using API 20NE (bio-
Merieux, Marcy l’Etoile, France).
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Table 1
Demographic details for patients in each P. aeruginosa infection category in April 1999
Chronic Intermittent Free Never
Number (%) 26 (18%) 50 (34%) 41 (28%) 29 (20%)
Number male (%) 11 (42%) 24 (48%) 29 (71%) 14 (48%)
Mean age in years (S.D.) 13.0 (2.2) 9.6 (4.5) 10.1 (4.0) 6.1 (4.0)
Mean number of months in previous year when 10.7 9.8 7.7 7.4
sample taken (range) (7–12) (4–12) (2–12)* (1–11)*
Mean% of months in previous year when 82.2% 23.7% 0% 0%
sample taken and qve for P. aeruginosa
Three patients in the ‘free’ group and three patients in the ‘never’ group were sampled less than our recommended four times per year.*
2.4. Patients
Initially an 11-year retrospective analysis of all 232
patients receiving all their CF care at the Leeds Regional
Paediatric Cystic Fibrosis Centre between October 1989
and December 2000 was performed to determine the
proportion of patients in each category per month, and
the future risk of growing P. aeruginosa for patients
defined as ‘free’ or ‘never’ (Total patient months
assessed 17 230).
The relationship between categorisation and clinical
data was assessed in April 1999. All patients who had
received all their CF care at the Leeds Paediatric CF
Centre for at least 12 months were included in the cross-
sectional analysis. Clinical and demographic data was
collected as near as possible to the end of the 12-month
period. Two investigators (KB and SC) assessed
Shwachman–Kulczycki (SK) w19x and Northern chest
X-ray scores w20x, and another investigator (TL) then
determined patients’ P. aeruginosa infection categories
for April 1999. The percent-predicted FEV was record-1
ed for all patients old enough to perform this test
reproducibly w21x and height and weight measurements,
and calculated body mass indices were compared to a
standard non-CF population w22x. P. aeruginosa antibody
levels were also recorded, and were considered positive
if )16 w6x.
The value of the categorisation in predicting future
infection status was assessed by taking all those patients
who had been attending the clinic and having cough
swabs or sputum samples taken for at least 12 months
in April 1994, and who were still present in the clinic
in April 1999. Patients were classified by the new
definition both in April 1994 and April 1999.
The clinical variables associated with each P. aerugi-
nosa infection category were then compared. All varia-
bles changed linearly with age. Since age and sex were
possible confounding factors the analyses have adjusted
for these when appropriate with age included in the
parametric models (analysis of covariance) as a linear
covariate. For non-parametric analyses the response
variable was regressed on age (and sex, if appropriate)
and the residuals were analysed using the Kruskal–
Wallis test. The x test was used to assess the relation-2
ships between P. aeruginosa infection category and a
positive P. aeruginosa antibody test, and infection cate-
gory in 1994 to infection category in 1999.
3. Results
Microbiological data allowing classification on the
basis of Pseudomonas aeruginosa sputum culture status
was available for all 232 patients receiving full-care at
the centre during the period 1990–2000. During the
total 17 230 patient months assessed, patients were
defined as ‘chronic’ for 3793 months (22.0%), ‘inter-
mittent’ for 5355 months (31.1%), ‘free’ for 4084
months (23.7%), and ‘never’ for 3998 (23.2%) months.
During this period the risk of a new growth of P.
aeruginosa in those patients classified as ‘free’ or
‘never’ was 4.1 and 2.2% per month, respectively (P-
0.02).
Clinical data was available for all 146 patients who
had been receiving their full care at the centre for at
least 12 months in April 1999 (Table 1), although the
28 youngest children were unable to perform FEV1
assessment. The largest group was the ‘intermittent’
category, and there was a high proportion of males in
the ‘free’ category.
The association between infection category and SK
score was highly significant (P-0.0001), with progres-
sively lower SK scores as severity of P. aeruginosa
categorisation increased from ‘never’ through to ‘chron-
ic’ (Table 2). Age and sex had no significant association
with SK score, and were removed from the model. The
difference between the ‘chronic’ group and the other
categories was significant. Northern chest X-ray score
was significantly associated with age and sex, and when
these were adjusted for the effect of P. aeruginosa
infection category remained highly significant (P-
0.0043), with the ‘chronic’ score significantly worse
than in the ‘free’ and ‘never’ categories. The percent-
predicted FEV was significantly associated with sex,1
and following appropriate adjustment the association
with infection category was highly significant (P-
0.0003). The ‘chronic’ and ‘intermittent’ groups’ per-
cent-predicted FEV s were significantly lower than those1
in the ‘free’ and ‘never’ groups.
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Table 2
New classification and relationship to Shwachman–Kulczycki score, Northern chest X-ray score, and % predicted FEV1
Chronic Intermittent Free Never
Mean SK score (S.D.) 74.5 (14.9) 86.6 (8.9) 88.3 (10.4) 92.7 (5.4)
Mean Northern score (S.D.) 9.2 (3.9) 6.3 (2.8) 5.7 (2.9) 4.0 (1.7)
wmean adjusted for age and sexx w8.0x w6.3x w5.8x w5.2x
Mean percent-predicted FEV (S.D.)1 64.4 (19.2) 69.8 (17.6) 83.1 (19.8) 83.4 (12.3)
wmean adjusted for sexx w65.1x w69.6x w81.1x w84.9x
Table 3
New classification and relationship to height (cm), weight (kg), and body mass index (BMI)
Chronic Intermittent Free Never
Mean height (S.D.) 148.3 (14.3) 130.7 (28.0) 135.1 (23.4) 111.6 (24.4)
wmean adjusted for agex w128.7x w131.1x w132.0x w132.5x
Mean height SDS (S.D.) y0.94 (0.98) y0.75 (1.13) y0.45 (0.92) y0.49 (0.99)
wmean adjusted for agex wy1.11x wy0.74x w–0.47x wy0.30x
Mean weight (S.D) 40.7 (11.2) 31.5 (15.3) 33.9 (15.8) 22.4 (11.4)
wmean adjusted for agex w30.0x w31.8x w32.5x w33.6x
Mean weight SDS (S.D.) y0.73 (1.00) y0.52 (1.06) y0.16 (0.96) y0.14 (0.99)
wmean adjusted for agex wy0.71x wy0.52x wy0.16x wy0.16x
Mean BMI (S.D.) 18.1 (2.3) 17.3 (2.3) 17.5 (2.3) 16.0 (1.8)
wmean adjusted for agex w17.3x w17.3x w17.4x w17.8x
Mean BMI SDS (S.D.) y0.25 (0.99) y0.05 (1.02) 0.18 (0.92) 0.30 (0.87)
wmean adjusted for agex wy0.04x wy0.06x w0.21x w0.07x
Table 4
New classification and relationship to P. aeruginosa antibody level (positive if )16)
Chronic Intermittent Free Never
Mean P. aeruginosa antibody 156.0 (105.9) 35.0 (56.2) 24.0 (72.9) 2.0 (8.0)
level (S.D.)
Number P. aeruginosa 26 (100%) 19 (38%) 12 (29%) 2 (7%)
antibody positive (%)
Number P. aeruginosa antibody 0 31 (62%) 29 (71%) 27 (93%)
negative (%)
Table 5
Table demonstrates association between patients’ categorisation in
April 1994 with their categorisation in April 1999
1999 1994
Chronic Intermittent Free Never
Chronic 7 5 6 2
Intermittent 1 7 11 11
Free 0 5 13 9
Never 0 0 0 7
It was necessary to adjust for age when analysing the
association between infection category and height, and
following this infection category had no significant
association (Table 3). However, when height standardi-
sed scores (SDS) were assessed, it was demonstrated
that those in the ‘chronic’ group were significantly
shorter than the ‘never’ group (Ps0.032). Adjustment
for age was also required when assessing the association
between infection category and weight and body mass
index, after which infection category was not signifi-
cantly associated with these parameters. Similarly, after
age adjustment, there was no significant association
between infection category and weight and body mass
index SDS scores.
The association between infection category and P.
aeruginosa antibody level required adjustment for age
(Table 4). Following this the association with infection
category was highly significant (P-0.0001), with a
significantly higher P. aeruginosa antibody level in the
chronic group when compared to the other three cate-
gories. When a P. aeruginosa antibody level of )16
was considered positive w6x, ‘chronic’ patients were
significantly associated with a positive antibody result
(P-0.001), and ‘never’ with a negative antibody result
(P-0.001).
The predictive value of infection status in determining
status five years later was assessed among the 84
patients who had been seen in the centre since 1994
(Table 5). Of those patients defined as ‘chronic’ in 1994
seven (88%) remained chronic in 1999, significantly
more than would be expected if this definition had no
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predictive value (P-0.001). In contrast, only 29% of
those classed as ‘intermittent’ in 1994 had progressed
to ‘chronic’ by 1999.
4. Discussion
The purpose of this study was to determine the value
of a new definition for chronic Pseudomonas aeruginosa
infection in cystic fibrosis patients, allowing patients to
be categorised into one of four groups according to the
results of monthly sputum cultures over the preceding
year. The results show that this new definition has good
face validity, and demonstrates the importance of iden-
tifying these four subgroups of patients. We therefore
suggest that this new definition is more useful than
previous definitions.
The clinical data demonstrates that chronic P. aeru-
ginosa infection is associated with worse SK clinical
score, worse Northern chest X-ray score, worse percent-
predicted FEV , and a reduction in height standard1
deviation score when compared to uninfected patients,
in keeping with previous studies w2,7,23,24x. The latter
acknowledge that many patients grow P. aeruginosa
intermittently, but the clinical characteristics of this
subgroup have not previously been separately analysed.
Nor are there any studies assessing patients free of P.
aeruginosa for more than 12 months (these have been
previously categorised within the intermittent or first
detection group) w7,8x. It is clear from our data that
these patients are very different clinically and prognost-
ically from other children with cystic fibrosis.
4.1. Relevance for treatment
These present data suggest that our previous definition
‘the regular culture of P. aeruginosa from the sputum
or respiratory secretions, on two or more occasions,
extending over six months’ would falsely categorise the
many patients with a new incidence of P. aeruginosa as
chronically infected w6x. When a routine cough swab or
sputum culture demonstrates a new growth of P. aeru-
ginosa the patient is called back to clinic for commence-
ment of early eradication therapy and further cultures
are taken w7,9x. Patients with chest exacerbations requir-
ing treatment also receive more frequent cultures than
obtained in routine surveillance. This biases heavily
towards a definition of chronic P. aeruginosa according
to our previous definition w6x. Indeed 46 patients would
have been classified as chronic in April 1999 compared
to 28 under our new definition. Many such patients
become free of P. aeruginosa following treatment, and
it would be inappropriate for them to receive intensive
chronic P. aeruginosa treatment protocols.
The Copenhagen definition uses a precipitin tech-
nique, which is well validated but not widely available
w7x. When precipitins have not been measured, chronic
P. aeruginosa infection is defined as persistent presence
of P. aeruginosa for 6 consecutive months. Patients
classified as ‘chronic’ under our new definition have
only 82.2% of months when sputum samples are taken
in which P. aeruginosa is cultured. These patients are
clinically very different from those who are classified
as ‘intermittent’, and are significantly predisposed to
remaining chronically infected. Only 15 of these 28
patients would be identified by the Copenhagen criteria
without the support of precipitin results.
The German definition uses a similar chronic P.
aeruginosa infection definition as in our study, although
they further subdivide this based on the presence of
non-mucoid or mucoid strains w8x. In practice this
subdivision does not affect treatment decisions, as evi-
dence suggests that the entire group should be on
intensive antibiotic treatment and mucolytics such as
DNase w10,25x. They do not differentiate between those
classed as ‘intermittent’ and ‘free’, but our data dem-
onstrates that these are very different groups.
4.2. Relevance for clinic management
We have assessed the relative risk of patients in each
diagnostic category growing P. aeruginosa in their spu-
tum in any given month. For those patients classed as
‘never’ or ‘free’, the chance of growing P. aeruginosa
is small (2 and 4%, respectively), and they are not a
high risk for infecting other patients. ‘Chronic’ patients
have an 82% chance of growing P. aeruginosa, strength-
ening the case for cohorting these patients to reduce the
risk of cross-infection. Patients who are classed as
‘intermittent’ have a 24% risk of growing P. aeruginosa
each month and ideally these patients should also be
kept separate from those classed as ‘never’ or ‘free’
w26x.
4.3. Relevance for predicting future infection status
An important feature for any definition of chronic P.
aeruginosa infection should be that it has predictive
value. As well as demonstrating an association with
changes in respiratory function and clinical scores, it
should also be shown to be of value in predicting a
patient’s P. aeruginosa infection status in the future. In
our study 88% of patients defined as chronically infected
remained in this category five years later. This is also
of value over the short term, as of the 26 patients
defined as ‘chronic’ in April 1999, 22 remained ‘chron-
ic’ in April 2000 (85%). This compares favourably to
both the Copenhagen definition (11 of 15 remaining
chronic (73%)) w7x, and our previous definition (34 of
46 remaining chronic (74%)) w6x. In addition, our data
demonstrate that with appropriate treatment patients
defined as ‘intermittent’ are most likely to remain in
this category when reassessed 5 years later, with as
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many patients (29%) in this category reverting to ‘free’
as progressing to ‘chronic’.
A high proportion (71%) of the patients in the ‘free’
group were male. Females outnumbered males in the
other three groups. The relevance of this finding requires
further investigation.
4.4. Relevance for research and audit
P. aeruginosa is an important pathogen in cystic
fibrosis, and much research into the effects of this
organism as well as improved treatment strategies is
being undertaken worldwide. For valid comparisons to
be made between different studies it is important that a
consensus is reached on the most appropriate definition
for chronic P. aeruginosa infection. The increasing use
of national databases to compare the results between
centres also requires a definition that does not bias
against those centres who perform sputum surveillance
more frequently, or places too much emphasis on differ-
ing precipitin or antibody tests.
5. Conclusions
This study demonstrates the value of an improved
clinical definition for chronic P. aeruginosa infection.
In particular it demonstrates the importance of identify-
ing patients growing P. aeruginosa intermittently to
facilitate appropriate treatment. Adoption of a suitable
definition is necessary to ensure both improved treatment
for people with cystic fibrosis and an increased under-
standing of the effects of P. aeruginosa infection.
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